Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, noviembre 18
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
ABVC BioPharma Inc
ABVC
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.9104
-0.0296
-3.15%
al cierre: Nov 18, 4:00 PM EST
$0.9000
-0.0104
-1.14%
After hour: 9:25 AM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Finanzas
Sentimiento
Comparar
Opciones
Informe de acciones
ABVC BioPharma Financials
ABVC BioPharma (ABVC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ABVC BioPharma Q1 EPS $(0.06), Same YoY
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Abvc Biopharma Says Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon; Reports Material Weakness In Internal Controls Over Financial Reporting For FY25
- SEC Filing
Benzinga Newsdesk
PRO
ABVC BioPharma Q3 EPS $(0.05) Down From $(0.03) YoY, Sales $795.950K Up From $389.276K YoY
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.05) per share. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $795.950 thousand in
Benzinga Newsdesk
PRO
ABVC BioPharma Q2 EPS $(0.13) Down From $(0.09) YoY
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.13) per share. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year.
Benzinga Newsdesk
PRO
ABVC BioPharma Determined That It Has A Material Weakness In Its Internal Controls Over Financial Reporting; Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
- SEC Filing
Benzinga Newsdesk
PRO
ABVC BioPharma Q3 EPS $(0.02) Up From $(0.82) YoY, Sales $389.28K Up From $15.88K YoY
Benzinga Newsdesk